🎉 M&A multiples are live!
Check it out!

Abivax Valuation Multiples

Discover revenue and EBITDA valuation multiples for Abivax and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

Abivax Overview

About Abivax

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.


Founded

2013

HQ

France
Employees

61

Website

abivax.com

Financials

LTM Revenue $8.8M

LTM EBITDA -$185M

EV

$153M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Abivax Financials

Abivax has a last 12-month revenue of $8.8M and a last 12-month EBITDA of -$185M.

In the most recent fiscal year, Abivax achieved revenue of n/a and an EBITDA of -$145M.

Abivax expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Abivax valuation multiples based on analyst estimates

Abivax P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $9.2M XXX XXX XXX
Gross Profit -$49.7M -$55.4M XXX XXX XXX
Gross Margin -Infinity% -601% XXX XXX XXX
EBITDA -$145M -$182M XXX XXX XXX
EBITDA Margin -Infinity% -1969% XXX XXX XXX
Net Profit -$45.2M -$76.3M XXX XXX XXX
Net Margin -Infinity% -827% XXX XXX XXX
Net Debt n/a $20.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Abivax Stock Performance

As of March 14, 2025, Abivax's stock price is EUR 5 (or $6).

Abivax has current market cap of EUR 346M (or $378M), and EV of EUR 141M (or $153M).

See Abivax trading valuation data

Abivax Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$153M $378M XXX XXX XXX XXX $-2.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Abivax Valuation Multiples

As of March 14, 2025, Abivax has market cap of $378M and EV of $153M.

Abivax's trades at 17.5x LTM EV/Revenue multiple, and -0.8x LTM EBITDA.

Analysts estimate Abivax's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Abivax and 10K+ public comps

Abivax Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $153M XXX XXX XXX
EV/Revenue 16.6x XXX XXX XXX
EV/EBITDA -0.8x XXX XXX XXX
P/E -2.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Abivax Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Abivax Valuation Multiples

Abivax's NTM/LTM revenue growth is -22%

Abivax's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.3M for the same period.

Over next 12 months, Abivax's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Abivax's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Abivax and other 10K+ public comps

Abivax Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -1969% XXX XXX XXX XXX
EBITDA Growth 25% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1991% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Abivax Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Abivax M&A and Investment Activity

Abivax acquired  XXX companies to date.

Last acquisition by Abivax was  XXXXXXXX, XXXXX XXXXX XXXXXX . Abivax acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Abivax

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Abivax

When was Abivax founded? Abivax was founded in 2013.
Where is Abivax headquartered? Abivax is headquartered in France.
How many employees does Abivax have? As of today, Abivax has 61 employees.
Who is the CEO of Abivax? Abivax's CEO is Mr. Marc de Garidel.
Is Abivax publicy listed? Yes, Abivax is a public company listed on PAR.
What is the stock symbol of Abivax? Abivax trades under ABVX ticker.
When did Abivax go public? Abivax went public in 2015.
Who are competitors of Abivax? Similar companies to Abivax include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Abivax? Abivax's current market cap is $378M
What is the current revenue of Abivax? Abivax's last 12-month revenue is $8.8M.
What is the current EBITDA of Abivax? Abivax's last 12-month EBITDA is -$185M.
What is the current EV/Revenue multiple of Abivax? Current revenue multiple of Abivax is 17.5x.
What is the current EV/EBITDA multiple of Abivax? Current EBITDA multiple of Abivax is -0.8x.
Is Abivax profitable? Yes, Abivax is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.